Lesinidase alfa

Drug Profile

Lesinidase alfa

Alternative Names: Recombinant alpha-N-acetyl-glucosaminidase (rhNAGLU) - Alexion; SBC-103

Latest Information Update: 02 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synageva BioPharma
  • Developer Alexion Pharmaceuticals
  • Class Acetylglucosaminidases; Enzymes; Glycoside hydrolases; Recombinant proteins
  • Mechanism of Action Alpha N acetyl D glucosaminidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 17 Apr 2018 Alexion Pharmaceuticals terminates a phase I/II trial in Mucopolysaccharidosis III (In children, Treatment-naive) in United Kingdom after review of the data from all interventional clinical studies of SBC-103 (NCT02618512)
  • 16 Feb 2017 Alexion Pharmaceuticals does not intend to expand a phase I/II trial in Mucopolysaccharidosis III (In children) (NCT02324049)
  • 12 Jan 2017 Alexion Pharmaceuticals completes a phase I/II clinical trials in Mucopolysaccharidosis III (In adolescents, In adults) in Netherlands (IV) (EudraCT2015-000753-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top